Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
NCT02169180Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in mantle cell lymphoma (MCL), sponsored by Janssen Pharmaceutical. Started Aug 2014; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02169180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169180.